Company attributes
Other attributes
Metacrine is a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal (GI) and liver diseases. Its most advanced program targets the farnesoid X receptor (FXR), which is central to modulating GI and liver diseases. Company believes that potency, sustained exposure and continuous target engagement are key to optimizing therapeutic benefit with an FXR targeted therapy. Leveraging our extensive chemistry and biology expertise, it has built a proprietary library of over 2,500 FXR compounds and have selected MET642 to advance into a Phase 2 study in ulcerative colitis.